<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="576">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04532554</url>
  </required_header>
  <id_info>
    <org_study_id>PR0015</org_study_id>
    <nct_id>NCT04532554</nct_id>
  </id_info>
  <brief_title>Growth Hormone in Obese Cases With Covid-19</brief_title>
  <official_title>The Impact of Growth Hormone in Obese Cases With Covid-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ClinAmygate</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ClinAmygate</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is well known that lymphoid organs such the thymus, the spleen and peripheral blood
      produce growth hormone (GH) and GH receptor is expressed on different subpopulations of
      lymphocytes. Many in vitro and in animal studies demonstrate an important role of GH in
      immunoregulation. GH stimulates T and B cells proliferation and immunoglobulin synthesis,
      enhances the maturation of myeloid progenitor cells and is also able to modulate cytokine
      response.

      The use of growth hormone in obese cases with COVID-19 may help them to recover earlier.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No participants enrolled
  </why_stopped>
  <start_date type="Anticipated">October 26, 2020</start_date>
  <completion_date type="Anticipated">December 20, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need for hospitalization</measure>
    <time_frame>one to two weeks</time_frame>
    <description>need to be hospitalized due to deterioration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>one to four weeks</time_frame>
    <description>Time to recovery from symptoms and signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of reduction in CRP</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Percentage of reduction in CRP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of reduction in LDH</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Percentage of reduction in LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of reduction in Ferritin</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Percentage of reduction in Ferritin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recovery from leucopenia</measure>
    <time_frame>one to two weeks</time_frame>
    <description>Time to recovery from leucopenia</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Recombinant GH will be used for those patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline will be used</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Growth Hormone</intervention_name>
    <description>Recombinant growth hormone will be used</description>
    <arm_group_label>Growth hormone</arm_group_label>
    <other_name>Recombinant growth hormone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Saline injection with the same amount</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Obese with BMI &gt; 30

        Exclusion Criteria:

          -  History of hypersensitivity to GH
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emad R Issak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assalam Clinics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asalam</name>
      <address>
        <city>Maadi</city>
        <state>Cairo</state>
        <zip>11433</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>https://www.researchgate.net/publication/7329964_Effect_of_growth_hormone_GH_on_the_immune_system</url>
    <description>Effect of growth hormone (GH) on the immune system.</description>
  </link>
  <results_reference>
    <citation>Meazza C, Pagani S, Travaglino P, Bozzola M. Effect of growth hormone (GH) on the immune system. Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:490-5. Review.</citation>
    <PMID>16444180</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 24, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

